Drug interactions
Rimegepant + Tepotinib
Severity: Moderate
Rimegepant and Tepotinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tepotinib inhibits P-glycoprotein and may increase rimegepant absorption and exposure. This could heighten adverse effects.
What this interaction means in plain words
Rimegepant and Tepotinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Rimegepant belongs to Central Nervous System; Tepotinib belongs to Oncology.
Why it happens
Tepotinib inhibits intestinal P-gp efflux of rimegepant.
What to do
Avoid repeat rimegepant dosing within 48 hours and monitor for adverse effects such as nausea and hypersensitivity.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Rimegepant and Tepotinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rimegepant
Other interactions of Tepotinib
- Colchicine + Tepotinib Major
- Digoxin + Tepotinib Major
- Tepotinib + Vincristine Major
- Amiodarone + Tepotinib Moderate
- Apixaban + Tepotinib Moderate
- Atorvastatin + Tepotinib Moderate
Frequently asked questions
Can I take Rimegepant with Tepotinib?
MediHelp rates the interaction as moderate. Rimegepant and Tepotinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tepotinib inhibits P-glycoprotein and may increase rimegepant absorption and exposure. This could heighten adverse effects.
How serious is the interaction between Rimegepant and Tepotinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid repeat rimegepant dosing within 48 hours and monitor for adverse effects such as nausea and hypersensitivity.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
